Insulin resistance in heart failure: widening the divide between reduced and preserved ejection fraction?

about

Metabolic Dysfunction in Heart Failure: Diagnostic, Prognostic, and Pathophysiologic Insights From Metabolomic Profiling.Serum insulin-like growth factor-1 and its binding protein-7: potential novel biomarkers for heart failure with preserved ejection fraction.

P2860

Q33892283-605BE217-0473-45DD-8499-AF2435CD3A1B Q36171125-2119ADBB-BE53-4FE1-BB2B-745836B37291

P2860

Insulin resistance in heart failure: widening the divide between reduced and preserved ejection fraction?

Item

http://www.wikidata.org/entity/Q46466507

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Insulin resistance in heart fa ...... d preserved ejection fraction?

@en

Insulin resistance in heart fa ...... d preserved ejection fraction?

@nl

type

Item

label

Insulin resistance in heart fa ...... d preserved ejection fraction?

@en

Insulin resistance in heart fa ...... d preserved ejection fraction?

@nl

prefLabel

Insulin resistance in heart fa ...... d preserved ejection fraction?

@en

Insulin resistance in heart fa ...... d preserved ejection fraction?

@nl

P1476

Insulin resistance in heart fa ...... d preserved ejection fraction?

@en

P2093

Stephen J Greene

http://www.w3.org/2001/XMLSchema#string

P2860

A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation

Effects of intensive glucose lowering in type 2 diabetes

Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial

Insulin resistance and inflammatory activation in older patients with systolic and diastolic heart failure.

Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes.

Critical appraisal of the obesity paradox in cardiovascular disease: how to manage patients with overweight in heart failure?

The war against heart failure: the Lancet lecture.

Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure.

P304

991-993

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1002/EJHF.337

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Gregg C. Fonarow

P577

2015-09-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26377227

http://www.w3.org/2001/XMLSchema#string

Insulin resistance in heart failure: widening the divide between reduced and preserved ejection fraction?

about

P2860

P2860

Insulin resistance in heart failure: widening the divide between reduced and preserved ejection fraction?

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698